The fight against diabetes is a continuing one, and the latest soldier to be recognized in this battle is West Caldwell, New Jersey-based EastGate Biotech Corp. (OTC:ETBI), which announced today positive Phase II Clinical Results of its innovative liquid insulin mouth rinse solution for Type 2 diabetes patients.
The 90-day Phase II clinical study was conducted in Pakistan. The human clinical trial is estimated to enroll 50 Type 2 patients currently on metformin treatment. Interim results are based on the first 30 patients who took a regiment of 25 IU of Insugin, a recombinant human liquid insulin mouth rinse twice a day at mealtime along with 500 mg of Metformin.
The Phase II study assessed safety, tolerability, pharmacokinetics and efficacy. A placebo arm was also incorporated in the clinical protocol.
The test found that Insugin offers unique benefits and the product’s goal is to slow down progression of Type 2 diabetes mellitus and reduce complications;
It was also found that Insugin displayed a good safety and tolerability profile.
EastGate CEO Anna Gluskin said, "While we are excited about all of the findings of this Phase II study with our innovative liquid insulin mouth rinse, we met our primary goal which was to demonstrate the safety and efficacy of Insugin."
Shares more than doubled early Wednesday afternoon, jumping 44-100ths of a cent, or 102.3%, to 87-100ths of a cent, on a towering volume of 37.6 million shares.
